Search

Your search keyword '"Malin, Jakob J."' showing total 136 results

Search Constraints

Start Over You searched for: Author "Malin, Jakob J." Remove constraint Author: "Malin, Jakob J."
136 results on '"Malin, Jakob J."'

Search Results

1. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

2. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

4. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

5. Key summary of German national treatment guidance for hospitalized COVID-19 patients: Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)

9. HIV-Infektion

10. Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients: Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)

11. Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19

14. Immune response to mRNA ‐based COVID ‐19 booster vaccination in people living with HIV

16. Antivirale Medikamente

17. Antivirale Medikamente

18. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

19. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen

20. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

21. Key summary of German national treatment guidance for hospitalized COVID-19 patients (Jul, 10.1007/s15010-021-01645-2, 2021)

22. Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS-CoV-2 mRNA vaccination

23. Antiviral drugs Potent agents, promising therapies for COVID-19 and therapeutic limitations

24. SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma

25. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

26. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

27. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

28. Recommendations for the Outpatient Drug Treatment of Patients With COVID-19

29. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations:a systematic guideline review

30. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

31. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

33. SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma

35. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

36. Key summary of German national treatment guidance for hospitalized COVID-19 patients

37. SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma

39. Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients

40. Key summary of German national treatment guidance for hospitalized COVID-19 patients

41. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

42. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19

43. Remdesivir against COVID-19 and Other Viral Diseases

44. Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19

45. 22 - HIV-Infektion

46. Key summary of German national treatment guidance for hospitalized COVID-19 patients

47. Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020

Catalog

Books, media, physical & digital resources